14 May 2026 Recon: FDA upheaval prompts some biotechs to move early trials abroad; AZ’s Imfinzi combo boosts bladder cancer survival in late-stage trial Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
12 May 2026 Recon: Makary to resign as FDA commissioner; EU reaches draft deal on Critical Medicines Act Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
11 May 2026 Recon: Makary’s fate as FDA commissioner up in the air; Roche to buy PathAI for $750M Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
07 May 2026 Recon: FDA to reconsider Atara, Pierre Fabre drug after surprise rejection; Amazon to stock Ozempic at US kiosks Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
05 May 2026 Recon: Kennedy urges Americans to quit SSRIs; BioNTech to scale back production, cut 1,860 jobs Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
04 May 2026 Recon: Amgen plans $300M manufacturing expansion in Puerto Rico; France fines Novo, Lilly over weight-loss drug ads Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
30 Apr 2026 Recon: FDA approves Axsome drug to treat agitation in Alzheimer’s patients; HHS appeals ruling on Kennedy’s vaccine policies Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
28 Apr 2026 Recon: Supreme Court to consider skinny labeling case; Opioid settlement likely after Purdue Pharma sentencing Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing Recon
27 Apr 2026 Recon: J&J eyes AI for potential to slash drug development time; UK biotech investment on the rebound Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
23 Apr 2026 Recon: FDA approves Regeneron’s hearing loss gene therapy; Novo’s oral diabetes drug reduced blood sugar in children in Phase 3a study Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
21 Apr 2026 Recon: FDA approves Merck’s HIV pill combo; Moderna gets EU nod for combined flu, COVID shot in older patients Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
20 Apr 2026 Recon: Lilly to acquire Kelonia for up to $7B; Trump issues order to speed psychedelic drug access Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
